Adaptive Biotechnologies
ADPT
133 hedge funds and large institutions have $2.58B invested in Adaptive Biotechnologies in 2019 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 22 closing their positions.
95% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 22
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 117 → 133 (+16)
4.13% more ownership
Funds ownership: 65.29% → 69.42% (+4.1%)
3% more capital invested
Capital invested by funds: $2.5B → $2.58B (+$87.1M)
68% less call options, than puts
Call options by funds: $1.61M | Put options by funds: $4.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.9M |
| 2 |
BlackRock
New York
|
+$36.2M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$15.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.2M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
-$30.7M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$13.9M |
| 3 |
JP Morgan Chase
New York
|
-$11.8M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$5.47M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$5.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
151
Tower Research Capital (TRC)
New York
| – | -$2K | -54 | Closed |
|
|
FCA
152
FinTrust Capital Advisors
Greenville,
South Carolina
| – | -$1K | -30 | Closed |
|
153
US Bancorp
Minneapolis,
Minnesota
| – | +$29 | +1 | New |
|
|
MAM
154
Meeder Asset Management
Dublin,
Ohio
| – | +$172 | +6 | New |
|
|
OPS
155
Orion Portfolio Solutions
Omaha,
Nebraska
| – | +$172 | +6 | New |
|
ADPT Hedge Fund Activity: Q4 2019 in Review
133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2019, worth a combined $2.58B — up 3.5% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ADPT positions and 22 closed out — a net gain of 21 holders — while 44 added to existing stakes and 29 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $42.9M. The largest seller was Fred Alger Management, cutting an estimated $30.7M.
- 133 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2019, up from 117 in Q3 2019.
- Funds reported $2.58B of Adaptive Biotechnologies stock for Q4 2019, up 3.5% quarter-over-quarter.
- 43 funds opened new Adaptive Biotechnologies positions in Q4 2019 and 22 closed out, a net change of +21 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2019 was T. Rowe Price Associates, an estimated $42.9M added.
- The largest Adaptive Biotechnologies seller in Q4 2019 was Fred Alger Management, an estimated $30.7M sold.
Based on aggregated 13F filings for Q4 2019.